Pamidronate
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Pamidronate
Pamidronate is a approved stage product being developed by Novartis for Bone Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT00738257. Target conditions include Bone Loss.
What happened to similar drugs?
9 of 20 similar drugs in Bone Loss were approved
Approved (9) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00128297 | Approved | Completed |
| NCT00738257 | Approved | Completed |
Competing Products
20 competing products in Bone Loss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 40 |
| Enzalutamide | Astellas Pharma | Phase 2 | 35 |
| Enzalutamide | Astellas Pharma | Phase 2 | 35 |
| Tacrolimus | Astellas Pharma | Phase 2 | 35 |
| Tacrolimus | Astellas Pharma | Phase 2 | 35 |
| Merestinib | Eli Lilly | Phase 1 | 21 |
| FORTEO + Placebo | Eli Lilly | Phase 1 | 29 |
| Arzoxifene + Placebo | Eli Lilly | Phase 3 | 40 |
| Tanezumab | Eli Lilly | Phase 3 | 40 |
| Anastrozole + Tamoxifen | AstraZeneca | Phase 3 | 40 |
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 40 |
| Zoledronic acid | Novartis | Phase 3 | 40 |
| Zoledronic acid + Letrozole | Novartis | Phase 3 | 40 |
| Zoledronic acid | Novartis | Phase 3 | 40 |
| Nilotinib | Novartis | Phase 1 | 29 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 43 |
| Zoledronic acid | Novartis | Phase 3 | 32 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 40 |
| zoledronic acid | Novartis | Phase 1 | 29 |
| Ruxolitinib continuous therapy | Novartis | Phase 2 | 39 |